{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:47:40Z","timestamp":1785898060888,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2023-C-001"],"award-info":[{"award-number":["CSH-2023-C-001"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.diabet.2026.101778","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:25:43Z","timestamp":1782343543000},"page":"101778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors"],"prefix":"10.1016","volume":"52","author":[{"given":"Chih-Feng","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Jung","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-5497","authenticated-orcid":false,"given":"Gwo-Ping","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2026.101778_bib0001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2026.101778_bib0002","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2337\/dc17-1962","article-title":"Global economic burden of diabetes in adults: projections from 2015 to 2030","volume":"41","author":"Bommer","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101778_bib0003","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2337\/dci23-0085","article-title":"Economic costs of diabetes in the U.S. in 2022","volume":"47","author":"Parker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101778_bib0004","first-page":"402","article-title":"Effects of clopidogrel and proton pump inhibitors on cardiovascular events in patients with type 2 diabetes mellitus after bare metal stent implantation: a nationwide cohort study","volume":"35","author":"Lee","year":"2019","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.diabet.2026.101778_bib0005","article-title":"Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study","volume":"16","author":"Chen","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabet.2026.101778_bib0006","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/PPA.S32745","article-title":"Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?","volume":"6","author":"Abdulameer","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.diabet.2026.101778_bib0007","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.clnesp.2024.12.009","article-title":"The paradoxical relationship among diabetes mellitus, osteoporosis and sarcopenia: the PARADOS Study","volume":"65","author":"Tiftik","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.diabet.2026.101778_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116373","article-title":"Fractures in type 2 diabetes confer excess mortality: the Dubbo osteoporosis epidemiology study","volume":"159","author":"Sheu","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.diabet.2026.101778_bib0009","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.hrthm.2021.03.046","article-title":"Antidiabetic drugs for preventing atrial fibrillation: a new revolution?","volume":"18","author":"McIntyre","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.diabet.2026.101778_bib0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13543784.2022.2022122","article-title":"New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs","volume":"31","author":"Katsenos","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.diabet.2026.101778_bib0011","first-page":"242","article-title":"Are there any renoprotective effects of sglt2 inhibitors in heart transplant recipients with diabetes?","volume":"41","author":"Lu","year":"2025","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.diabet.2026.101778_bib0012","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00198-024-07126-0","article-title":"Association of combined healthy lifestyle factors with incident osteoporosis in patients with and without type 2 diabetes","volume":"35","author":"Chen","year":"2024","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.diabet.2026.101778_bib0013","article-title":"Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures","volume":"60","author":"Wikarek","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.diabet.2026.101778_bib0014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11892-020-01361-5","article-title":"Impact of type 2 diabetes mellitus and antidiabetic medications on bone metabolism","volume":"20","author":"Lee","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabet.2026.101778_bib0015","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12020-024-04070-1","article-title":"The effect of antidiabetic drugs on bone metabolism: a concise review","volume":"87","author":"Psachna","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.diabet.2026.101778_bib0016","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamainternmed.2024.7357","article-title":"Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors","volume":"185","author":"Shin","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabet.2026.101778_bib0017","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00198-023-06908-2","article-title":"Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"34","author":"Wang","year":"2023","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.diabet.2026.101778_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3170","article-title":"Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis","volume":"35","author":"Li","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabet.2026.101778_bib0019","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/cpt.3626","article-title":"Use of sodium-glucose transport protein 2 inhibitors and the incidence of urolithiasis: a multi-database and cross-country study in patients with type 2 diabetes mellitus","volume":"117","author":"Chung","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diabet.2026.101778_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70122","article-title":"Risk of new-onset ischaemic and haemorrhagic stroke in patients with type 2 diabetes with chronic kidney disease on SGLT-2 inhibitor users: a population-based cohort study","volume":"42","author":"Lin","year":"2026","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabet.2026.101778_bib0021","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.diabet.2019.01.010","article-title":"Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials","volume":"45","author":"Cheng","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2026.101778_bib0022","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MNH.0000000000000505","article-title":"Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus","volume":"28","author":"Vinke","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.diabet.2026.101778_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117912","article-title":"Effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin and canagliflozin, on the musculoskeletal system in an experimental model of diabetes induced by high-fat diet and streptozotocin in rats","volume":"184","author":"Londzin","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.diabet.2026.101778_bib0024","doi-asserted-by":"crossref","first-page":"E178","DOI":"10.1503\/cmaj.240922","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1-3 chronic kidney disease","volume":"197","author":"Tsai","year":"2025","journal-title":"CMAJ"},{"key":"10.1016\/j.diabet.2026.101778_bib0025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2026.101778_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2025.112935","article-title":"SGLT2 inhibitor, bone metabolism biomarkers, and osteoporosis risk: a mendelian randomization study","volume":"211","author":"Wang","year":"2025","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.diabet.2026.101778_bib0027","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:07:24Z","timestamp":1785895644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363626000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1262363626000571"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101778","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101778"}}